Advertisement
Advertisement
U.S. markets open in 2 hours 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Perrigo Company plc (PRGO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
42.58-0.40 (-0.93%)
At close: 04:00PM EDT
42.58 0.00 (0.00%)
After hours: 07:13PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close42.98
Open43.05
Bid0.00 x 1300
Ask0.00 x 3100
Day's Range42.51 - 43.59
52 Week Range31.32 - 50.90
Volume1,589,865
Avg. Volume1,334,666
Market Cap5.729B
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.82
Earnings DateAug 09, 2022
Forward Dividend & Yield1.04 (2.45%)
Ex-Dividend DateSep 01, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-61% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PRGO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Perrigo Company plc
    Analyst Report: Perrigo Company plcPerrigo is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company’s product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement